OAT and safer-supply services: patient care, business resilience and Ontario’s October 2026 changes

How a properly supported OAT or clinic service can fit a pharmacy business, and what the October 13 CPSO announcement changes for safer-supply prescribing.

Educational owner resource. Read the cited sources and obtain advice for your circumstances.

Start with the service need

Well-supported opioid agonist treatment can connect people living with opioid use disorder to ongoing care. Methadone is one OAT option; other options include buprenorphine. Treatment selection and supervision are clinical decisions. The business case should begin with a service the pharmacy can provide safely and consistently, not a target for prescription volume. Health Canada

OAT and safer supply are distinct approaches. Health Canada describes an established evidence base for OAT and an evolving evidence base for safer-supply services. The terms should not be used interchangeably, nor should one service be presented as a guaranteed clinical or commercial outcome. Health Canada

What CPSO announced on October 13, 2026

CPSO approved additional Ontario physician-prescribing safeguards. Safer-supply prescriptions are to accompany OAT; prescription instructions must identify safer supply and rule out take-home doses; and the physician must conduct an in-person clinical assessment at least monthly. CPSO expects transition to compliance by November 16, 2026. The announcement does not ban safer-supply prescribing. College of Physicians and Surgeons of Ontario

These changes concern safer-supply prescribing by Ontario physicians. They do not mean every methadone or other OAT prescription has lost carry eligibility. They do not announce a pharmacy payment increase. Owners should have their clinical team confirm current prescriptions, professional guidance and implementation arrangements rather than applying a blanket rule to all patients.

Where an integrated pharmacy or clinic can benefit

For an appropriately resourced service, the potential advantages include continuity, predictable service routines, better communication across the care team and an additional clinically relevant capability. Co-location can make coordination easier when patient choice, consent and professional independence are protected. These are potential operating benefits, not a promise of higher patient volume or a referral entitlement.

From an owner’s perspective, established processes and a capable team may make the service more transferable. Regular service contacts can support the wider care relationship, but patient needs must determine care. A buyer will assess the service’s contribution after its actual delivery costs, not reward activity automatically.

How the October change can affect operations

The business implications are an assessment, not a CPSO earnings forecast. A service affected by supervised safer-supply requirements may need more observation capacity, suitable hours, documentation, clinical coordination and relief coverage. Monthly in-person physician reviews can affect appointment capacity and the continuity plan for a clinic that previously relied on less frequent review.

Before forecasting growth, model staff time, coverage, secure handling, premises, training, reconciliation, insurance and disruption. Examine concentration in a prescriber or programme and any dependence on arrangements that may change. Additional supervision can increase costs; it does not establish a higher pharmacy margin.

What an owner and buyer should verify

OCP’s opioid policy sets professional expectations for pharmacists, including competence and specific OAT requirements. A clinic relationship does not remove pharmacy obligations. Services should be organised around respectful care, safe delivery and appropriate professional guidance. Ontario College of Pharmacists

Confirm who is accountable for clinical decisions, prescription clarification, supervision and follow-up, and how coverage continues during absences or a sale.
Review staff training, operating procedures, security, records and incident response with qualified professionals. Do not place patient details in an acquisition marketing document.
Reconcile service revenue to the resources needed to deliver it and review current payer/programme rules separately. Do not assume funding continues unchanged.
Assess arrangements for lawful, patient-centred coordination. Do not create payments or commitments that purchase referrals or restrict patient choice.
For a sale, present anonymised service-level economics and a continuity plan. Keep patient records and clinical diligence in a separately authorised secure process.

A stronger service can support a stronger business

A sustainable, well-governed service may broaden a pharmacy’s capability and make earnings easier to understand. Unresolved compliance, prescriber concentration or undercosted supervision can have the opposite effect. Neither OAT nor safer supply automatically earns a higher acquisition multiple.

This owner resource is dated October 14, 2026 and is not a clinical protocol. Review the October announcement and current professional requirements with the responsible pharmacist and prescriber before changing care or forecasting transaction value.

Continue reading

Pharmacy financial figures: gross profit, gross margin, NOI and EBITDA

Pharmacy share or asset purchase agreement: what sellers should expect

Selling a pharmacy in Canada: what happens from an accepted offer to closing?

Sources and context

CPSO Board approves stronger safer-supply prescribing safeguards
Ontario physician-prescribing announcement; transition expected by November 16, 2026. Do not apply safer-supply no-carries changes to every OAT prescription or treat them as a pharmacy reimbursement increase.

Opioid use disorder and treatment
General treatment information. Clinical decisions and provincial requirements need qualified current review; not a pharmacy earnings forecast.

Safer supply and opioid agonist treatment
Distinguishes OAT from safer supply; evidence for safer-supply services is evolving. Does not establish Ontario program economics or a guaranteed patient outcome.

Opioid Policy
Pharmacy professional expectations, training, OAT operations and patient-centred care. Does not certify a particular store or authorize referral arrangements.

Browse all articles and exit guides →

Plan your next conversation

Smith & Bederman Advisory Group supports independent Canadian pharmacy owners with sales, acquisitions, valuation and succession planning.

Explore valuation and EBITDA tools · Check exit readiness · Book a confidential consultation

Calculator access, full buyer profiles and downloads are available through the Resource Centre’s access form.